Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eye (Lond) ; 2024 Jul 08.
Artigo em Inglês | MEDLINE | ID: mdl-38977819

RESUMO

BACKGROUND/OBJECTIVES: Immediate sequential bilateral cataract surgery (ISBCS) was first introduced into NICE guidelines in 2017. In this approach, patients undergo cataract surgery on both eyes on the same day. Although increasingly popular, only 0.5% of all cataract operations nationally are performed using this approach. We redesigned our service to routinely offer ISBCS and are now one of the leading NHS providers of ISBCS in the UK. We audited our cataract operations in 2022 and report our initial experiences with ISBCS here. SUBJECTS/METHODS: We redesigned our cataract service to routinely offer ISBCS on the NHS. We audited all cataract operations performed in calendar year 2022. RESULTS: We performed 4652 NHS cataract operations including 498 (10.7%) operations on 249 patients using the ISBCS approach. Trainee surgeons performed 32.5% of these cases. There were two intraoperative complications, both during the second eye operation. One was a suspected suprachoroidal haemorrhage and the other was a posterior capsular rupture post lens implantation. Post-operatively there was one case of retinal detachment requiring vitrectomy following uncomplicated ISBCS and five cases of Irvine-Gass syndrome that were managed medically. CONCLUSIONS: From this data, ISBCS does not pose a greater risk to patients in terms of complications. Allowing trainees to operate on ISBCS cases improves the trainee experience. With appropriate pre-operative counselling, patients listed for unilateral surgery can be converted to ISBCS on the day of operation to fully utilise theatre capacity. Patients listed for ISBCS can also be converted to unilateral surgery on the day of operation when surgeons need time to deal with complications safely.

2.
Eye (Lond) ; 2024 May 23.
Artigo em Inglês | MEDLINE | ID: mdl-38783083
4.
Eye (Lond) ; 37(10): 2069-2076, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-36274084

RESUMO

BACKGROUND: Innovative technology is recommended to address the current capacity challenges facing the NHS. This study evaluates the patient acceptability of automated telephone follow-up after routine cataract surgery using Dora (Ufonia Limited, Oxford, United Kingdom), which to our knowledge is the first AI-powered clinical assistant to be used in the NHS. Dora has a natural-language, phone conversation with patients about their symptoms after cataract surgery. METHODS: This is a prospective mixed-methods cohort study that was conducted at Buckinghamshire Healthcare NHS Foundation Trust. All patients who were followed up using Dora were asked to give a Net Promoter Score (NPS), and 24 patients were randomly selected to complete the validated Telephone Usability Questionnaire (TUQ) as well as extended semi-structured interviews that underwent thematic analysis. RESULTS: A total of 170 autonomous calls were completed. The median NPS score was 9 out of 10. The TUQ (scored out of 5) showed high rates of acceptability, with an overall mean score of 4.0. Simplicity, time saving, and ease of use scored the highest with a median of 5, whilst 'speaking to Dora feels the same as speaking to a clinician' scored a median of 3. The main themes extracted from the qualitative data were 'I can see why you're doing it', 'It went quite well actually', 'I just trust human beings I suppose'. CONCLUSION: We found high levels of patient acceptability when using Dora across three acceptability measures. Dora provides a potential solution to reduce pressure on hospital capacity whilst also providing a convenient service for patients.


Assuntos
Catarata , Telefone , Humanos , Estudos de Coortes , Estudos Prospectivos , Seguimentos
6.
Br J Ophthalmol ; 100(2): 204-8, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26085546

RESUMO

BACKGROUND: Percutaneous sclerotherapy is an alternative to surgery for the treatment of orbital lymphatic malformations (LMs). We present a large series of patients undergoing sclerotherapy for macrocystic LMs with detailed visual acuity (VA) outcome data. METHODS: Data were collected prospectively in all patients with macrocystic orbital LMs undergoing sclerotherapy. Sclerotherapy was performed under general anaesthesia, instilling sodium tetradecyl sulfate under imaging control. Procedures were repeated at 2-week to 6-week intervals, depending on clinical response. Patients underwent ophthalmological assessment, ultrasound and/or MRI before and after treatment. PRIMARY OUTCOME MEASURE: change in maximal radiological diameter of the LM. SECONDARY OUTCOME MEASURE: change in VA after treatment. RESULTS: 29 patients underwent 71 procedures (1-8 procedures per patient) over 6.7 years. Mean age=7.31 years. 11 patients (37.9%) had undergone previous treatment, including excision biopsy, drainage and decompression. All patients presented with proptosis and/or pseudoptosis. 23 patients (79.3%) had decreased VA at presentation. Average follow-up was 21.8 months (range 3-75 months). All patients achieved a reduction in maximal lesion diameter of ≥50%, with complete radiological resolution in 51.7% (n=15). VA improved in 18/23 patients (78.2%). Average logMAR before treatment=0.43 (SD ±0.47); average after treatment=0.25 (SD ±0.32); p<0.01. There was one complication (1.4%): one patient required a lateral canthotomy for an intralesional haematoma 2 h after sclerotherapy. CONCLUSIONS: Sclerotherapy is a safe and highly effective treatment for orbital LMs with excellent VA outcomes. It should be considered as the first-line treatment for this condition.


Assuntos
Linfangioma Cístico/terapia , Anormalidades Linfáticas/terapia , Neoplasias Orbitárias/terapia , Escleroterapia , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Linfangioma Cístico/diagnóstico por imagem , Anormalidades Linfáticas/diagnóstico por imagem , Vasos Linfáticos/patologia , Imageamento por Ressonância Magnética , Masculino , Neoplasias Orbitárias/diagnóstico por imagem , Estudos Retrospectivos , Soluções Esclerosantes/uso terapêutico , Tetradecilsulfato de Sódio/uso terapêutico , Tomografia Computadorizada por Raios X , Ultrassonografia , Acuidade Visual/fisiologia , Adulto Jovem
8.
J Plast Reconstr Aesthet Surg ; 64(12): 1661-4, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21741889

RESUMO

Ossifying fibroma is a rare benign tumour of the craniofacial skeleton, which can have an aggressive biological behaviour in the paediatric population. Complete surgical excision, where possible, is the ideal. This case report discusses the multidisciplinary, surgical management of two complex cases of large juvenile ossifying fibroma (JOF), involving the orbit. Both patients underwent resection of the orbital ossifying fibroma with no macroscopic evidence of recurrence at 4 years follow-up. Full functional outcome was achieved with preservation of vision and facial nerve function as well as good facial symmetry and aesthetics. The successful surgical outcome of these cases was due to a combination of a multidisciplinary team approach, rigorous pre-operative planning, maximal tumour resection, and the use of a novel surgical technique involving a medial zygomatic-orbito-maxillary rotational osteotomy.


Assuntos
Fibroma Ossificante/cirurgia , Neoplasias Orbitárias/cirurgia , Osteotomia/métodos , Adolescente , Criança , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Seio Maxilar/patologia , Recidiva Local de Neoplasia , Equipe de Assistência ao Paciente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...